DAY ONE BIOPHARMACEUTICALS, INC. DAWN 深 滬
等待開盤 09-11 09:30:00 美东时间
7.26
-0.150
-2.02%
華盛通- 最 高7.46
- 今 開7.40
- 成交量 87.17万股
- 最 低 7.21
- 昨 收 7.41
- 總市值 7.33亿
- 52周最高 16.76
- 市盈率 靜 --
- 換手率 0.86%
- 52周最低 5.635
- 委 比 -15.31%
- 總股本 1.01亿
- 歷史最高 28.699
- 量 比 1.01
- 振 幅 3.37%
- 歷史最低 5.44
- 每 手 1
- 風險率 1.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多累计研发投入近500亿后，恒瑞医药上半年业绩迎来“爆发”
炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源 | 野马财经 作者 | 赵晴 创新药贡献6成营收，对外...
08-25 21:31
Ionis Pharmaceuticals Gains FDA Approval for DAWNZERA
An announcement from Ionis Pharmaceuticals ( ($IONS) ) is now available. On Aug...
08-22 02:27
FDA Approves Ionis' DAWNZERA As First RNA-Targeted Therapy For Hereditary Angioedema, Offering Longest Dosing Option With Q4W Or Q8W Administration
- DAWNZERA demonstrated significant and sustained HAE attack rate reduction and long-term disease control -- Offers longest dosing option for HAE, with dosing every 4 or 8 weeks -- Compelling profile supported by
08-21 23:46
恒瑞医药上半年营收157.6亿，国际化BD签约金额超百亿美元
8月20日，恒瑞医药（股票代码：600276.SH；01276.HK）发布2025年半年度报告。报告期内，公司实现营业收入157.61亿元，同比增长15.88...
08-21 19:45
恒瑞医药(01276)2025年半年报：营收、净利双创新高，业绩强势增长
8月20日，恒瑞医药(股票代码：600276.SH；01276.HK)发布2025年半年度报告。报告显示，2025年上半年，公司实现营业收入157.61亿元，同...
08-20 19:48
Piper Sandler initiates coverage of oncology companies
Piper Sandler launched coverage for a few biotech companies in the oncology space, as mentioned below: CG Oncology (NASDAQ:CGON) rated Overweight with a $55 price target: "Investor expectations for cr...
08-19 23:17
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers BiomX (AMEX:PHGE) shares moved upwards by 40.1% to $0.61 during Tuesda...
08-06 05:07
Day One Biopharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 revenue results.
Day One Biopharmaceuticals shares are trading lower after the company reported ...
08-06 04:04
Day One Reports Second Quarter 2025 Financial Results and Corporate Progress
Day One Biopharmaceuticals reported Q2 2025 net product revenue of $33.6 million for OJEMDA, a 10% Q/Q increase, with full-year guidance of $140-$150 million. OJEMDA prescriptions exceeded 1,000 in Q2, a 15% increase Q/Q and 346% Y/Y. The company ended Q2 with $453.1 million in cash. R&D expenses decreased 60% Y/Y, while SG&A decreased 4% Y/Y. Day One also announced the termination of its VRK1 program collaboration. The company will host a confer...
08-05 20:00
